Dominik A. Barth

Graz, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study.

Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study.

Journal: Clinical genitourinary cancer

Published: October 08, 2024

Arterial thromboembolic events in testicular cancer patients: short- and long-term incidence, risk factors, and impact on mortality.

Arterial thromboembolic events in testicular cancer patients: short- and long-term incidence, risk factors, and impact on mortality.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 25, 2024

Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors.

Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors.

Journal: JACC. CardioOncology

Published: June 11, 2024

Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.

Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.

Journal: Journal for immunotherapy of cancer

Published: November 16, 2023

Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of Prostate Biopsy Outcome.

Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of Prostate Biopsy Outcome.

Journal: Cancer genomics & proteomics

Published: January 25, 2023

Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.

Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.

Journal: Biology of sex differences

Published: January 25, 2023

Optimization of postoperative surveillance protocols in upper tract urothelial cancer: A retrospective cohort study.

Optimization of postoperative surveillance protocols in upper tract urothelial cancer: A retrospective cohort study.

Journal: Frontiers in oncology

Published: January 12, 2023

Preoperative fibrinogen/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery.

Preoperative fibrinogen/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery.

Journal: World journal of urology

Published: January 11, 2023

MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.

MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.

Journal: RNA biology

Published: December 05, 2022

A chemokine network of T cell exhaustion and metabolic reprogramming in renal cell carcinoma.

A chemokine network of T cell exhaustion and metabolic reprogramming in renal cell carcinoma.

Journal: Frontiers in immunology

Published: November 11, 2022

A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer.

A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer.

Journal: The Prostate

Published: August 21, 2022

Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.

Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.

Journal: Therapeutic advances in medical oncology

Published: March 11, 2022

Showing 1-12 of 37

Last Updated: 09/26/2026